Xenon Pharmaceuticals Inc. financial data

Symbol
XENE on Nasdaq
Industry
Pharmaceutical Preparations
Location
200 3650 Gilmore Way, Burnaby, British Columbia, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.48K % +10.1%
Debt-to-equity 4.23 % -17.9%
Return On Equity -24.7 % +5.11%
Return On Assets -23.7 % +4.28%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 76.2M shares +16.5%
Common Stock, Shares, Outstanding 75.8M shares +16.6%
Entity Public Float 2.44B USD +29.9%
Common Stock, Value, Issued 1.44B USD +28.5%
Weighted Average Number of Shares Outstanding, Basic 77.9M shares +18.1%
Weighted Average Number of Shares Outstanding, Diluted 77.9M shares +18.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 192M USD +19.1%
General and Administrative Expense 63.5M USD +49.7%
Operating Income (Loss) -256M USD -25.4%
Nonoperating Income (Expense) 41.7M USD +40.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -214M USD -22.9%
Income Tax Expense (Benefit) -446K USD -142%
Net Income (Loss) Attributable to Parent -213M USD -21.9%
Earnings Per Share, Basic -2.83 USD/shares -5.99%
Earnings Per Share, Diluted -2.83 USD/shares -5.99%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 87.6M USD -12%
Marketable Securities, Current 566M USD +32.6%
Accounts Receivable, after Allowance for Credit Loss, Current 938K USD +16.5%
Assets, Current 660M USD +24.2%
Deferred Income Tax Assets, Net 1.05M USD +75.4%
Property, Plant and Equipment, Net 10.2M USD -0.72%
Operating Lease, Right-of-Use Asset 8.26M USD -13%
Assets 836M USD +24.6%
Employee-related Liabilities, Current 8.94M USD +52.8%
Liabilities, Current 29.7M USD +20%
Operating Lease, Liability, Noncurrent 8.4M USD -13.9%
Liabilities 38.1M USD +10.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.34M USD
Retained Earnings (Accumulated Deficit) -834M USD -34.4%
Stockholders' Equity Attributable to Parent 798M USD +25.3%
Liabilities and Equity 836M USD +24.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.2M USD -25.5%
Net Cash Provided by (Used in) Financing Activities 7.88M USD -93.4%
Net Cash Provided by (Used in) Investing Activities -46.2M USD -199%
Common Stock, Shares, Issued 75.8M shares +16.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -89.7M USD -831%
Deferred Tax Assets, Valuation Allowance 214M USD +30.2%
Operating Lease, Liability 9.79M USD -11.1%
Payments to Acquire Property, Plant, and Equipment 188K USD -91.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -209M USD -19.5%
Lessee, Operating Lease, Liability, to be Paid 11.1M USD -12.7%
Operating Lease, Liability, Current 1.39M USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.82M USD +4.13%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.75M USD +4.24%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Deferred Income Tax Expense (Benefit) 403K USD +39.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.31M USD -23.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.8M USD -0.5%
Deferred Tax Assets, Operating Loss Carryforwards 120M USD +48.7%
Preferred Stock, Shares Issued 0 shares -100%
Unrecognized Tax Benefits 10.9M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.1M USD -38.6%
Operating Lease, Payments 411K USD +1.23%
Preferred Stock, Shares Outstanding 0 shares -100%
Deferred Tax Assets, Net of Valuation Allowance 802K USD +57.6%